Hyperhomocysteinemia. An emerging and important risk factor for thromboembolic and cardiovascular disease.
Homocysteine is an important contributing factor to thrombosis, vascular injury, and vascular disease. Mechanisms for homocysteine-induced vascular disease include alterations in coagulation as well as endothelial cell and vessel wall injury. Hyperhomocysteinemia (HH[e]) can occur when homocysteine metabolism is altered by mutations in enzymes responsible for homocysteine metabolism. Characterization of these mutations identifies patient groups at risk for vascular disease. Treatment of HH(e) consists of vitamins and raises the possibility that some forms of vascular disease may be easily, safely, and inexpensively treated.
Guba
S C
SC
Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, USA.
Fink
L M
LM
Fonseca
V
V
D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology*; D006710:Homocysteine / Q000097:blood* / Q000235:genetics; D006711:Homocystine; D006801:Humans; D008715:Methionine / Q000378:metabolism; D012307:Risk Factors; D013923:Thromboembolism / Q000097:blood / Q000209:etiology*; D013927:Thrombosis; D014815:Vitamins / Q000627:therapeutic use
D014815:Vitamins; D006710:Homocysteine; D006711:Homocystine; D008715:Methionine